logo
Spain's Train Crisis Was A Wake-Up Call. Could Hydrail Trains Be The Answer?

Spain's Train Crisis Was A Wake-Up Call. Could Hydrail Trains Be The Answer?

Forbes16-05-2025

People wait outside the Atocha train station in Madrid after its closure as a massive power outage ... More hits Spain on April 28, 2025. Power went out across all of Spain and Portugal today, cutting cellphone and internet networks, halting trains and trapping people in elevators, officials said. The operator, Red Electrica, said it would likely take six to 10 hours to restore power in the country and urged people not to speculate as to the cause of the outage. (Photo by Thomas COEX / AFP) (Photo by THOMAS COEX/AFP via Getty Images)
In the middle of the day on 28 April 2025, Spain lived a modern replay of the 1951 sci-fi classic The Day the Earth Stood Still. In the film, paternalistic aliens cut electricity worldwide to force humanity to reconsider its nuclear arms race. In Spain's case, there were no aliens—just an all-too-human failure in the electric grid. But the result was eerily similar: everything stopped.
Like much of Europe, Spain's rail system still depends on 19th-century overhead electrification—a technology first developed in Tsarist Russia. What once marked a leap in industrial modernity has become an ageing and increasingly fragile network. A single fault in the grid, even hundreds of kilometres away, can bring entire train systems to a halt. That April day in Spain, it did exactly that.
Passengers stranded in the open countryside were the lucky ones. Those caught in tunnels faced a darker, more claustrophobic ordeal.
But this high-profile failure has cast new light on an alternative Spain has been quietly exploring for almost two decades: hydrail, or hydrogen-powered rail. Unlike conventional electric trains that depend on external power lines, hydrail carries its energy onboard in the form of compressed or liquid hydrogen. No wires. No dependency on the grid. Just trains that keep moving—even when everything else doesn't.
Widespread adoption of hydrail would have made the April paralysis all but impossible. More than that, it would represent a significant leap in energy diversification and resilience—two things climate-stressed infrastructure now urgently needs.
Spain wasn't caught entirely off guard. In fact, it was one of the first countries to seriously explore hydrogen-powered rail. In 2006, Dr Carlos Navas attended the Second International Hydrail Conference in Herning, Denmark. Two years later, he hosted the Fourth Conference in Valencia. By 2011, Spain's narrow-gauge operator FEVE had already demonstrated a hydrogen tram in the Principality of Asturias—years ahead of similar efforts in China or Germany.
Today, Spain is set to lead again. A recent breakthrough positions the country to pioneer high-speed hydrail. The driver? Economics. With low population density in many regions, Spain faces some of the highest per-passenger track electrification costs in Europe: "Very roughly," says Stan Thompson, co-founder of the Mooresville Hydrail Initiative, 'in US dollars, the capital cost of new track electrification is around $15 milion per track mile.' Hydrail, by contrast, offers a cheaper and more flexible solution that sidesteps the need for costly fixed-line electrification.
Spain is not alone. Germany is already running the Saltzgitter-built Coradia iLint. China has deployed hydrogen trams in Foshan. And this summer, the first U.S. hydrogen passenger line opens in California between San Bernardino and Redlands.
TOPSHOT - Passengers wait along a platform to board a train at Santa Justa railway station in ... More Seville on April 29, 2025, the day after a massive power cut affecting the entire Iberian peninsula and the south of France. Electricity was restored to almost all of Spain and Portugal on April 29 morning, allowing a gradual return to normal life in the two countries, which were hit on April 28 by a giant blackout that lasted up to ten or even twenty hours depending on the region. The return of power has enabled rail traffic to be restored on several major routes, including Madrid-Seville and Madrid-Barcelona, according to the national company Renfe. However, traffic remains suspended on several other major routes, as the authorities have given priority to restoring suburban trains. (Photo by CRISTINA QUICLER / AFP) (Photo by CRISTINA QUICLER/AFP via Getty Images)
Thompson – the man who coined the term 'hydrail' in 2003 – sees the writing on the wall for traditional electrification. 'With the soaring cost of copper as we 'electrify everything,' the old model is becoming unsustainable,' he says. New overhead lines are not only expensive to install—they're also costly to maintain, at roughly $150,000 per mile per year.
As long as the global push for electrification continues, copper is expected to remain a strategic bottleneck—and a rising cost factor in infrastructure projects like electrified rail. Copper prices are hitting record highs in 2025 due to unprecedented demand from the global energy transition, technological advancements, and infrastructure upgrades, all while supply growth is hampered by production challenges and slow mine development. Geopolitical uncertainty and trade policies are adding to the price volatility and upward pressure.
In a copper-scarce world, hydrail offers unique advantages: hydrail systems use substantially less copper than traditional electrified rail because they eliminate the need for copper-intensive trackside power delivery systems. Copper use is largely limited to the train itself, making hydrail a less copper-dependent technology for rail transport.
And Thompson believes that salvaging copper from existing electrified corridors may help finance the switch to hydrogen. 'When the first two or three overhead systems have gone hydrail,' Thompson predicts, 'the rest will come down like dominoes.' Slow dominoes, perhaps—but the 140-year lifespan of aging rail infrastructure is looking increasingly hard to justify.
And beyond cost, overhead train power has other drawbacks. Utility engineers aren't fans—ground currents from the lines can interfere with water systems, telecoms, and other underground infrastructure. City planners, too, have long been frustrated. Despite years of effort to bury power lines and telephone cables, railway corridors remain cluttered with conspicuous poles, wires, and metalwork.
People leave the Atocha train station in Madrid after its closure as a massive power outage hits ... More Spain on April 28, 2025. Power went out across all of Spain and Portugal today, cutting cellphone and internet networks, halting trains and trapping people in elevators, officials said. The operator, Red Electrica, said it would likely take six to 10 hours to restore power in the country and urged people not to speculate as to the cause of the outage. (Photo by Thomas COEX / AFP) (Photo by THOMAS COEX/AFP via Getty Images)
Curiously, the story of hydrail's potential to ride out power grid failures begins in the United States. In the early 2000s, the U.S. Congress funded development of the first hydrail locomotive under the George W. Bush administration. Built by BNSF Railways and Vehicle Projects LLC, the train wasn't just intended for freight—it was designed as a self-propelled mobile power plant, capable of supplying emergency electricity to hospitals and other critical infrastructure after natural disasters like hurricanes.
Its tractive power was successfully demonstrated on military bases in the Western U.S., but after the Bush presidency ended, so did government support. The locomotive—BNSF 1205—was scrapped for parts and now sits on display, minus its hydrogen components, at the Oklahoma Railway Museum.
But in 2025, Thompson believes the transition to onboard hydrogen-sourced electric power is inevitable, beginning with lighter equipment and shorter rail lines. As copper prices rise and aging infrastructure reaches the end of its life, the economic case for gridless rail becomes increasingly compelling.
A technology first imagined to keep the lights on during crises may now help avoid them altogether. But only time will tell the extent to which hydrail becomes the new norm beyond its current early use-cases in California, Germany and China. If Spain stays the course, it could be the first to show that hydrail isn't a far-off future. It's already on track.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Add-On D-Serine Shows Promise in Severe Depression
Add-On D-Serine Shows Promise in Severe Depression

Medscape

time5 hours ago

  • Medscape

Add-On D-Serine Shows Promise in Severe Depression

D-serine as an adjunctive treatment did not outperform placebo overall in patients with major depressive disorder (MDD), a new trial showed. However, depressive symptoms and anhedonia were significantly alleviated among patients with severe MDD, particularly among those on higher doses of standard medications. METHODOLOGY: Researchers conducted a 6-week, randomised, double-blind, placebo-controlled trial including 44 adult inpatients (mean age, 43.55 years; 45% women) diagnosed with moderate to severe MDD from Basel, Switzerland. Participants were randomly assigned in a 1:1 ratio to receive either D-serine (2 g/d) or placebo alongside standard treatment. The primary outcome was the change in clinician-rated depressive symptoms from baseline to post-intervention, measured using the 17-item Hamilton Depression Rating Scale. Secondary outcomes were self-reported depressive symptoms, anxiety, and anhedonia, measured using the Beck Depression Inventory-II, State-Trait Anxiety Inventory-1, and Snaith-Hamilton Pleasure Scale, respectively. TAKEAWAY: Both D-serine and placebo groups showed a significant reduction in symptoms across all measures, with no significant differences observed in the overall sample. In the subgroup analysis, D-serine significantly alleviated depressive symptoms in participants with severe MDD ( P = .02), with a trend towards reduction in anhedonia. = .02), with a trend towards reduction in anhedonia. In the D-serine group, clinical improvements were correlated with higher baseline depression severity and higher doses of standard medication. No serious adverse events were reported. IN PRACTICE: "DS [D-serine] may offer therapeutic benefits for patients with severe MDD, particularly when used alongside greater doses of TAU [treatment as usual] medication. These findings support the potential of DS as a synergistic adjunctive strategy to enhance the therapeutic effect of pharmacological interventions, especially in severe cases," the authors wrote. SOURCE: This study was led by Lukas Sempach, University of Basel, Basel, Switzerland. It was published online on May 26 in the Journal of Affective Disorders . LIMITATIONS: The small sample size limited the study's generalisability and reduced its power to detect small to moderate treatment effects, particularly in patients with severe depression. Additionally, the relatively low dose of D-serine used, along with its metabolism, may have limited its engagement with N-methyl-D-aspartate receptors. DISCLOSURES: This study was supported by the Gertrud Thalmann Foundation of the University Psychiatric Clinics Basel and the Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung. The authors reported having no conflicts of interest.

Summer Solstice 2025: Date, Time And How It Works
Summer Solstice 2025: Date, Time And How It Works

Forbes

time7 hours ago

  • Forbes

Summer Solstice 2025: Date, Time And How It Works

The sun rises at Stonehenge, near Amesbury, in Wiltshire, southern England on June 21, 2023, during ... More the Summer Solstice festival, which dates back thousands of years, celebrating the longest day of the year. (Photo by DANIEL LEAL/AFP via Getty Images) The June solstice marks the longest day of the year in the Northern Hemisphere and the shortest in the Southern Hemisphere. But what exactly causes this astronomical event? Here's everything you need to know about the summer solstice and the winter solstice in June 2025, including the dates and where to livestream it from Stonehenge in the U.K. Called the summer solstice in the Northern Hemisphere because it heralds the beginning of the new astronomical season of summer, the event takes place this year at precisely 02:42 UTC on Saturday, June 21, 2025 (10:42 p.m. EDT on Friday, June 20). The solstice is one of four major waymarkers of Earth's journey around the sun, the others being the other solstice in December and the two equinoxes in September and March. All are a consequence of the 23.5-degree tilt of Earth's axis with respect to the plane of the solar system. That tilt causes different parts of the planet to get more or less hours of daylight according to the time of year. It's the tilt that causes Earth's seasons. During the summer solstice, the Northern Hemisphere tilts toward the sun, allowing it to appear at its highest point in the sky at noon. The opposite is the case in the Southern Hemisphere. On the date of the June solstice, the sun shines directly overhead at the Tropic of Cancer, an imaginary line around Earth at 23.5 degrees north of the equator (through Mexico, India and Egypt). At the North Pole, the sun doesn't set, while at the South Pole, it doesn't rise. Though the solstice itself isn't easily perceptible, it is often associated with visible changes in the sun's path. The exact point on the horizon that the sun appears to rise and set changes throughout the year. On the June solstice, the sun rises at its most extreme point on the northeast horizon, reaches its highest point in the sky at noon, and sets at its most extreme point on the northwest horizon. It's for that reason that the solstice is celebrated at Stonehenge in the U.K., a monument that is thought to align with the rising sun on the date of the June solstice. English Heritage offers a YouTube livestream of the sunrise on the solstice. Wishing you clear skies and wide eyes.

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Yahoo

time9 hours ago

  • Yahoo

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation HighlightsVaroglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025Presentation time: 8:15 am CEST as part of the focused oral sessionTitle: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studiesVenue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the 'Company'), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor ContactsVivoryon Therapeutics Manuela Bader, Director IR & CommunicationEmail: IR@ LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@ Media ContactTrophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77Email: vivoryon@ Attachment 20250606_ERA_VVYSign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store